ISRCTN15803686进行中（未招募）2 期
A phase 2 open-label trial to evaluate safety, efficacy, tolerability, and pharmacodynamics of a combination of JNJ-73763989, nucleos(t)ide analogs, and a PD-1 inhibitor in chronic hepatitis B patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participants must have chronic hepatitis B virus (HBV) infection
- •2. Participants must have fibroscan liver stiffness measurement less than or equal to (<=) 9.0 kilopascal (KpA) or a liver biopsy result classified as metavir F0-F2
排除标准
- •1. Participants with evidence of hepatitis A virus infection (hepatitis A antibody immunoglobulin IgM), hepatitis C virus (HCV) infection (HCV antibody), hepatitis D virus (HDV) infection (HDV antibody), hepatitis E virus (HEV) infection (Hepatitis E antibody IgM) or human immunodeficiency virus type-1 (HIV-1) or human immunodeficiency virus type-2 (HIV-2) infection (laboratory confirmed) at screening
- •2. History or evidence of clinical signs or symptoms of hepatic decompensation, including but not limited to portal hypertension, ascites, hepatic encephalopathy, esophageal varices
- •3. Participants with history or signs of cirrhosis or portal hypertension or signs of hepatocellular carcinoma (HCC) or clinically relevant renal abnormalities
- •4. Participants with personal/familial history/indicative of immune-mediated disease risk
研究者
相似试验
进行中（未招募）
1 期
A Clinical Study to evaluate the effects of a Combination of JNJ-73763989, Nucleos(t)ide Analogs, and a PD-1 inhibitor in Chronic Hepatitis B Patients.Chronic Hepatitis B Virus InfectionMedDRA version: 20.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-005132-33-ESJanssen-Cilag International NV44
进行中（未招募）
1 期
A Clinical Study to evaluate the effects of a Combination of JNJ-73763989, Nucleos(t)ide Analogs, and a PD-1 inhibitor in Chronic Hepatitis B Patients.EUCTR2021-005132-33-FRJanssen-Cilag International NV44
已完成
2 期
A phase 2, open label trial of guadecitabine (SGI-110) in patients with T-cell lymphomaACTRN12618000028202Monash Health20
进行中（未招募）
1 期
This is an Open-label Study to evaluate the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys with Duchenne Muscular Dystrophy (DMD)Duchenne Muscular Dystrophy (DMD)MedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-003653-30-ITS Pharma, Inc20
进行中（未招募）
不适用
A Phase II, open-label study to assess the safety and efficacy of oral MEK162 in adults with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations - NDEUCTR2010-023412-13-ITOVARTIS FARMA54